Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

Actavis launches Ondansetron tablets in the U.S.

Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.

28 Jun 2007

Breakthrough in understanding of noroviruses

A breakthrough announced this week by scientists at the University of Southampton's School of Medicine will lead to greater understanding of noroviruses, the most common cause of non-bacterial gastroenteritis around the world.

27 Jun 2007

Abuse of prescription drugs

Increasingly, drug abusers are getting their next fix from their medicine cabinets, instead of from drug dealers.

26 Jun 2007

Morning sickness may indicate lower risk of breast cancer

It may not seem so at the time, but women who suffer through morning sickness during their pregnancies actually may be fortunate.

23 Jun 2007

Latest food scare... sesame seeds with Salmonella

In the latest food scare to hit North America the Canadian Food Inspection Agency (CFIA) is warning the public not to consume certain sesame seeds because they may be contaminated with Salmonella.

21 Jun 2007

New treatments for migraines and chronic headaches

Twelve percent of the population, three quarters of them women, suffer at least occasionally from migraines and about 5 percent from chronic headaches.

20 Jun 2007

Genzyme announces results of clinical trials of Renvela and Renagel

Genzyme Corp. has announced the results of two new studies comparing a powder form of Renvela (sevelamer carbonate) to Renagel tablets (sevelamer hydrochloride), including one trial in which patients received the powder form three times per day, and one in which it was administered once per day.

19 Jun 2007

Solvay Pharmaceuticals submits supplemental NDA for AndroGel

Solvay Pharmaceuticals, Inc., has announced that it submitted a supplemental New Drug Application (sNDA) for AndroGel (testosterone gel) 1% CIII to the U.S. Food and Drug Administration (FDA) for treatment in male adolescents ages 13-17 years old with primary or secondary hypogonadism.

17 Jun 2007

Colitis symptoms 27 years later

The unusual case of a woman whose symptoms of colitis emerged 27 years after she left the country in which she was infected is detailed in a Case Report in the Lancet.

17 Jun 2007

Priority review granted for oral formulation of HYCAMTIN (topotecan)

GlaxoSmithKline (GSK) has announced that its new drug application (NDA) for ORAL HYCAMTIN (topotecan) capsules, a treatment for relapsed small cell lung cancer (SCLC), has been granted Priority Review by the United States Food and Drug Administration (FDA).

14 Jun 2007

Asthma and allergic shock

Asthma, even a mild form, is the single most important factor that increases the risk of death from anaphylaxis (allergic shock), says a new report from Harvard Medical School, What To Do About Allergies .

14 Jun 2007

Steroid use among teen girls

Steroid use among teen girls is not limited to those involved in competitive athletics and is associated with a cluster of other health-harming behaviors, including smoking and taking diet pills, according to results of a national survey published in the June issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

5 Jun 2007

Axitinib shows promise in treatment of advanced thyroid cancer

The investigational drug axitinib produced tumor regression or stable disease in almost three-out-of-four patients with advanced thyroid cancer, a research team reported at the annual meeting of the American Society for Clinical Oncology in Chicago.

5 Jun 2007

Results of phase II studies of pazopanib

GlaxoSmithKline (GSK) has announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.

5 Jun 2007

FDA approves Norditropin for short stature in children with Noonan syndrome

Novo Nordisk has announced that Norditropin (somatropin[rDNA origin] injection) received U.S. Food and Drug Administration (FDA) approval for the treatment of short stature in children with Noonan syndrome.

3 Jun 2007

Once-fatal metabolic disorders treatable

People with a class of rare genetic disorders that often lead to brain damage, coma and death can be successfully treated with drugs, says a researcher at the Stanford University School of Medicine and Lucile Packard Children's Hospital.

1 Jun 2007

Groundbreaking robotic pancreatectomy

Surgeons at the University of Illinois Medical Center at Chicago performed a groundbreaking robotic pancreatectomy in a 39-year-old man to relieve him of debilitating pain.

1 Jun 2007

FDA completes review of FluMist

MedImmune, Inc. has announced that the U.S. Food and Drug Administration (FDA) has stated the agency has completed its review of all submissions made related to the supplemental biologics license application (sBLA) to extend the age indication of FluMist (Influenza Virus Vaccine Live, Intranasal).

28 May 2007

New weapons in the fight against food poisoning

University of Nottingham experts have joined forces with Canadian biotech company GangaGen Life Sciences Inc to develop new weapons in the fight against food poisoning.

28 May 2007

FDA approves treatment for bacterial vaginosis

Mission Pharmacal has announced that the U.S. Food and Drug Administration (FDA) approved Tindamax (tinidazole) for the treatment of bacterial vaginosis (BV), the most common vaginal infection among women of childbearing age in the United States.

28 May 2007